Compare MobilEye Global Inc (MBLY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs TransMedics Group Inc — how do they compare? MobilEye Global Inc trades at $7.17 (market cap $6.00B), while TransMedics Group Inc trades at $78.41 (market cap $2.74B). The key difference: MobilEye Global Inc is far larger — about 2.2× TransMedics Group Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MobilEye Global Inc for 15 Days and TransMedics Group Inc for 24 Days on average.
| MBLY | TMDX | |
|---|---|---|
Market Cap | $6.00B | $2.74B |
Volume | 7,007,849 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $15.42 | $150.42 |
52-Week Low | $6.56 | $61.99 |
Typical Hold Time | 15 Days | 24 Days |
Enterprise Value | $4.56B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye Global (MBLY) trades at $7.11, down 0.56% on the day, with a bearish technical outlook but mixed fundamental signals. The stock shows negative profitability with a net income margin of -201.49% for 2026, yet revenue grew to $2.0 billion. Recent earnings beats in Q1 and Q2 2026 contrast with a Q4 2025 miss, while analyst consensus is a 'Buy' with a $10.83 price target. News highlights ADAS momentum and a robotaxi strategy expansion, but the stock faces significant cash flow volatility.
The outlook for MBLY is cautious; while analyst optimism and revenue growth provide upside potential, persistent losses and bearish technicals pose risks. Investment opportunity hinges on execution of autonomous driving programs, but shareholders face volatility from negative earnings and high valuation multiples like EV/EBITDA of 32.34.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
